Stockscreener 앱 받기
5.11
3.04%
-0.16
시간 외 거래:
5.11
전일 마감가:
$5.27
열려 있는:
$5.24
하루 거래량:
1.52M
Relative Volume:
0.66
시가총액:
$728.71M
수익:
$181.41M
순이익/손실:
$-59.56M
주가수익비율:
-12.17
EPS:
-0.42
순현금흐름:
$-38.83M
1주 성능:
+7.58%
1개월 성능:
+16.67%
6개월 성능:
+50.29%
1년 성능:
+118.38%
1일 변동 폭
$5.10
$5.275
1주일 범위
$4.62
$5.39
52주 변동 폭
$2.095
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.11 | 728.71M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing - Seeking Alpha
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity - Defense World
Pallas Capital Advisors LLC Acquires New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Squarepoint Ops LLC Has $138,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Two Sigma Advisers LP Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings - Defense World
Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 5.5%Should You Sell? - MarketBeat
Leerink Partners raises Xeris Pharmaceuticals stock price target By Investing.com - Investing.com UK
Transcript : Xeris Biopharma Holdings, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 01 - MarketScreener
Xeris at Jefferies Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
xeris biopharma holds annual meeting, elects directors By Investing.com - Investing.com South Africa
xeris biopharma holds annual meeting, elects directors - Investing.com
Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug - Crain's Chicago Business
Xeris at Jefferies Conference: Strategic Growth and Future Prospects - Investing.com
Xeris Biopharma projects $1 billion Recorlev revenue by 2035 - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Rings the Closing Bell - Nasdaq
Transcript : Xeris Biopharma Holdings, Inc.Analyst/Investor Day - marketscreener.com
Xeris Biopharma Holdings, Inc. Reaffirms Revenue Guidance for the Year 2025 - marketscreener.com
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set - marketscreener.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day - mx.advfn.com
Xeris Unveils Strategy for Long-Term Growth and Value Creation a - GuruFocus
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million - marketscreener.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc. - Defense World
XERS: Key Highlights from Analyst and Investor Day | XERS Stock News - GuruFocus
ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $273,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Bank of America Corp DE Sells 17,544 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Deutsche Bank AG Grows Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Cut to “Hold” at Wall Street Zen - Defense World
Northern Trust Corp Purchases 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) With A Potential Upside Of More Than 18.7% - Stocksregister
Jane Street Group LLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Announces Details for Analyst & Investor Day | XERS Stock News - GuruFocus
Xeris Announces Details for Analyst & Investor Day - Business Wire
Balyasny Asset Management L.P. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
The Manufacturers Life Insurance Company Lowers Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Leerink Partnrs Estimates Xeris Biopharma Q2 Earnings - Defense World
Voya Investment Management LLC Reduces Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Raymond James Financial Inc. Purchases New Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Hsbc Holdings PLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Raised by Price T Rowe Associates Inc. MD - Defense World
Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Consensus Target Price from Analysts - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.10%
1.57%
자본화:
|
볼륨(24시간):